Evidence map›Paper›PMID 27620744›Full record

ArticleJournal of cancer research and clinical oncology2016

A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.

Hasan Raza Kazmi, Abhijit Chandra, Saket Kumar, Leena Khare Satyam, Annapurna Gupta, Jaya Nigam, Meenu Srivastava, Balraj Mittal

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Gallbladder cancer: Progress in the Indian subcontinent.World journal of clinical oncology · 2024
    Review
  2. Review
  3. Review
  4. Overview of current targeted therapy in gallbladder cancer.Signal transduction and targeted therapy · 2020
    Review
  5. Article
  6. microRNA Let-7b: A Novel treatment for endometriosis.Journal of cellular and molecular medicine · 2018
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Hasan Raza KazmiDepartment of Surgical Gastroenterology, King George's Medical University, Lucknow, 226003, India.
Abhijit ChandraDepartment of Surgical Gastroenterology, King George's Medical University, Lucknow, 226003, India. abhijitchandra@hotmail.com.
Saket KumarDepartment of Surgical Gastroenterology, King George's Medical University, Lucknow, 226003, India.
Leena Khare SatyamCell and Molecular Biology Department, Aurigene Discovery Technologies Limited, Bangalore, 560095, India.
Annapurna GuptaDepartment of Medical Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, 226003, India.
Jaya NigamDepartment of Surgical Gastroenterology, King George's Medical University, Lucknow, 226003, India.
Meenu SrivastavaDepartment of Surgical Gastroenterology, King George's Medical University, Lucknow, 226003, India.
Balraj MittalDepartment of Medical Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, 226003, India.
King George's Medical University · INSanjay Gandhi Post Graduate Institute of Medical Sciences · INAurigene Discovery Technologies (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGallbladder cancer is a lethal malignancy of hepato-biliary system with high incidence in North India, especially along gangetic plain. The let-7 microRNAs play a key role in regulating KRAS expression and a polymorphism in 3' untranslated region (rs61764370, T/G) of KRAS leads to its higher expression. This polymorphism is known to be associated with increased risk and prognosis of various cancers but its association with gallbladder cancer has not been evaluated. To address this research question, we evaluated whether rs61764370 variant is associated with gallbladder cancer susceptibility and clinical outcomes.

methodsIn present case-control study, we enrolled 541 patients with gallbladder malignancy and 307 controls. Genomic DNA was obtained from peripheral blood and genotyping was performed using Taqman allelic discrimination assay.

resultsHeterozygous (TG) individuals are at a significant higher risk for GBC as compared with wild genotype (TT) (p = 0.007, odds ratio = 2.56, 95 % CI 1.27-5.18). At allelic level, allele G has significant higher risk for GBC as compared with T allele (p = 0.008, odds ratio = 2.5, 95 % CI 1.25-5.01). Survival analysis reveals decrease in overall survival for heterozygous genotype (p < 0.0001, hazard ratio = 3.42, 95 % CI 1.21-4.20). Also, significant decrease in overall survival was observed for patient carrying allele G (p < 0.0001, HR = 2.89, 95 % CI 1.21-4.20) as compared with allele C.

conclusionsWe conclude that KRAS rs61764370 polymorphism is significantly associated with risk and prognosis of gallbladder malignancy in this endemic belt.

Indexed as

Polymorphism, Single Nucleotide3' Untranslated RegionsAdultAgedBinding SitesCase-Control StudiesFemaleGallbladder NeoplasmsGenetic Predisposition to DiseaseHumansIndiaMaleMicroRNAsMiddle AgedProto-Oncogene Proteins p21(ras)Risk Factors3' Untranslated RegionsKRAS protein, humanMicroRNAsmirnlet7 microRNA, humanProto-Oncogene Proteins p21(ras)Gallbladder cancerKRASlet-7rs61764370

Identifiers

PMID27620744
PMCPMC11819253
OpenAlexW2519761838

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.